Evidence map›Paper›PMID 33244223›Full record

ArticlePatient preference and adherence2020

Conditions for the Implementation of a Patient Education Program Dedicated to Cancer Patients Treated by Oral Anticancer Therapy.

Elise Verot, Claire Falandry, Véronique Régnier Denois, Corinne Feutrier, Boris Chapoton, Jean Okala, Sidonie Pupier, Vanessa Rousset, Françoise Bridet, Christine Ravot and 5 more

Abstract read
In one paragraph

Article in Patient preference and adherence, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Evaluation of illness perception and treatment adherence in patients taking oral chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Elise VerotUniversity of Lyon, University of Saint-Etienne, Centre Hygée, HESPER EA 7425, Rue de la Marandière, Saint-Priest-en- Jarez, 42270, France.ORCID 0000-0003-3274-8868
Claire FalandryOncogeriatrics Department, Lyon Sud Teaching Hospital & Claude Bernard University, Lyon, France.ORCID 0000-0001-7267-4723
Véronique Régnier DenoisUniversity of Lyon, University of Saint-Etienne, Centre Hygée, HESPER EA 7425, Rue de la Marandière, Saint-Priest-en- Jarez, 42270, France.ORCID 0000-0002-0293-5606
Corinne FeutrierTransversal Unit of Patient Education of Department of Rhône, Hospices Civils de Lyon, Lyon 69004, France.
Boris ChapotonUniversity of Lyon, University of Saint-Etienne, Centre Hygée, HESPER EA 7425, Rue de la Marandière, Saint-Priest-en- Jarez, 42270, France.
Jean OkalaPublic Health Department, Centre Hygée, Institut de Cancérologie Lucien Neuwirth, HESPER EA 7425, Saint-Priest-en-Jarez 42270, France.ORCID 0000-0003-4867-0372
Sidonie PupierPublic Health Department, Centre Hygée, Institut de Cancérologie Lucien Neuwirth, HESPER EA 7425, Saint-Priest-en-Jarez 42270, France.
Vanessa RoussetPublic Health Department, Centre Hygée, Institut de Cancérologie Lucien Neuwirth, HESPER EA 7425, Saint-Priest-en-Jarez 42270, France.
Françoise BridetTransversal Unit of Patient Education of Department of Rhône, Hospices Civils de Lyon, Lyon 69004, France.
Christine RavotOncogeriatrics Department, Lyon Sud Teaching Hospital & Claude Bernard University, Lyon, France.
Catherine RioufolPharmacy Department, Lyon Sud Teaching Hospital & Claude Bernard University, Lyon, France.
Véronique Trillet-LenoirMedical Oncology Department, Lyon Sud Teaching Hospital & Claude Bernard University, Lyon, France.
Magali HureauDepartment of Clinical Research and Innovation, Léon Bérard Cancer Centre, Lyon, France.
Franck ChauvinUniversity of Lyon, University of Saint-Etienne, Centre Hygée, HESPER EA 7425, Rue de la Marandière, Saint-Priest-en- Jarez, 42270, France.
Aurélie BourmaudClinical Epidemiology Unit, Robert Debré Hospital, AP-HP, INSERM CIC-EC 1426; INSERM 1123 ECEVE, University of Paris, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionA patient education program has been developed in the field of cancer for supporting cancer patients undergoing oral anticancer therapies. Its implementation was tested in 3 different settings. The objectives of this study were to 1) identify barriers and facilitators for implementing the patient education program, 2) identify practices encouraging or hindering implementation and 3) produce recommendations for its dissemination.

methodsTwenty semi-structured interviews were conducted with caregivers from all three establishments.

resultsThe main factors associated with successful implementation were as follows: prescribers' representations on patient education, considered of low value; on oral anticancer therapies, considered too dangerous to be handled by the patient him/herself, the indefinite legitimacy of certain professions in charge of patient education programs; patients' engagement in their care pathway and provision of caregivers.

conclusionRecommendations include developing patient education culture within the environment of the medical doctors' curriculum, to consider contextual, pre-existing cooperative units for implementing patient education, to systematically send patients to patient education programs without practicing triage. Successful implementation of patient education critically depends on the prescribing physicians' perceived value of patient education. Patient education should become mandatory, integrated as part of the cancer care pathway. Physicians lack the necessary time and/or means to assess patients' capacity for engagement, without adequate strategies for their support. Therefore, physicians should systematically refer all patients to patient education, where nurses can tailor their coaching of cancer patients.

trial registrationThe study protocol was approved by the IRB SUD EST I (N° EudraCT: 2016-A00113-48). All participants were given written and verbal information about the study and gave informed consent to participate.

Indexed as

implementation scienceoral anticancer therapypatient educationtheoretical domains framework

Identifiers

PMID33244223
PMCPMC7683887

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.